Data Exclusivity Rules Rile Canadian Generics Makers

Law360, New York (November 14, 2006, 12:00 AM EST) -- A month after Canada changed its patent rules to extend the period of data protection for brand-name drugs, the country’s generic drug industry has launched a legal attack on the amendment, arguing that the move will unfairly boost the balance sheets of pharmaceutical giants and deplete the health care system of millions of dollars.

The Canadian Generic Pharmaceutical Association said on Tuesday that it has filed an action with the Federal Court of Canada challenging the new federal regulations, which in part provide brand-name drug companies...
To view the full article, register now.